Influence of Opioids on Circulating Tumor Cells in Radical Cystectomy
NCT ID: NCT04358718
Last Updated: 2021-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
44 participants
INTERVENTIONAL
2020-06-02
2021-01-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Whether Opioids Are Factor That Induced POD?
NCT05596071
Opioid-free Anesthesia as an Alternative to General Anesthesia in Abdominal Surgery
NCT06380244
Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled
NCT05848635
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients
NCT02043366
Precision Analgesia for Cardiac Surgery
NCT05612399
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
general anesthesia
Patients in this group will receive general anesthesia with intraoperative and postoperative intravenous opioid-based analgesia.
general anesthesia
Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
general analgesia combined with epidural analgesia
Patients in this group will receive combined epidural and general anesthesia with intraoperative and postoperative epidural ropivacaine-based analgesia.
general anesthesia combined with epidural analgesia
Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
general anesthesia
Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
general anesthesia combined with epidural analgesia
Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA I-II
* Patients with primary bladder cancer of Stage T2a or higher, who are scheduled for robot-assisted laparoscopic radical cystectomy
* Written informed consent
Exclusion Criteria
* Palliative surgery
* Contraindications for epidural anesthesia
* Metastatic bladder cancer
* Patients with a history of any other malignancy
* Chronic opioids medication
* severe systemic disease (heart, lung, kidney, or immune system)
* Known hypersensitivity or suspected allergy to intervention drugs
* Intellectual Disability
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jie Tian
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wang X, Zhang S, Jin D, Luo J, Shi Y, Zhang Y, Wu L, Song Y, Su D, Pan Z, Chen H, Cao M, Yang C, Yu W, Tian J. mu-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial. Cancer Commun (Lond). 2023 Mar;43(3):365-386. doi: 10.1002/cac2.12408. Epub 2023 Feb 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTC20200417
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.